CHP2C9 PGx Testing & Warfain

CYP2C9 is part of a gene family that produces enzymes that are vital in breaking down and processing prescription medications. It has been estimated that more than 15% of prescription medications are affected by individual’s production of CYP2C9 enzymes. Studies have also shown that over a third of the caucasian population have a genetic variation that affects metabolization. For this reason, pharmacogenetic testing is recommended for patients beginning drug treatment or experiencing issues with drug treatment linked to this gene.

Medications Affected By CYP2C9 Genetics

Drugs that have been studied by their relation to CYP2C9 include angiotensin II blockers, alkylating anticancer prodrugs, non-steroidal anti-inflammatory drugs, and sulfonylureas (including diabetic medications). Specifically, the relationship between Warfarin (Coumadin®) tolbutamide, and phenytoin (Dilantin®). These medications could present issues in patients who have genetic variations of their CYP2C9 enzyme production. Both side effects and inefficacy have been reported in patients who receive standard dosages for these medications before discovering they have genetic variations that affect metabolization. Of the medications, the link between CYP2C9 and Warfarin is the most studied. Which is recommended that patients either beginning Warfarin treatment or who are currently on Warfarin but are experiencing issues received PGx testing.

Pharmacogentic Testing for Warfarin

As a blood thinner and treatment for blood clots, Warfarin presents high-risk side effects if an incorrect dosage is used. In PGx testing, individuals are categorized based on how genetic variation affects metabolization. As mentioned above studies have concluded that around a third of the caucasian population have a genetic variation that would make them a poor metabolizer of medications like Warfarin. Patients with this genetic variation may require dosages to be shifted based on risk. The chief risk of Warfarin chief risk is heavy bleeding. In patients, this can lead to complications and can even be deadly. It is highly recommended that PGx testing is used for patients before they begin Warfarin treatment.

Order PGx Testing Through TruGenX

TruGenX provides PGx testing for CYP2C9 and a variety of other important genes. Our tests can help physicians identify if their patient is genetically predisposed to having an abnormally poor or rapid metabolization rate. This can prevent complications, decrease the need for trial and error, and lead to better patient outcomes. If you are patient, please view our guide on PGx testing, and ask your doctor if PGx testing might be right for you. For licensed medical professionals, please contact our team to order PGx testing.